Besides, Riedel and coworkers (2021) evidenced that CRISPR/Cas9-mediated inactivation of Jun results in impaired prostate cancer cell proliferation and invasiveness in vitro and in vivo [192]. The gene discussed is JUN; the disease is prostate cancer.